The Healthcare IPO Resilience Test: Provider, Payer, or Pure Play Tech?

Disclaimer: The thoughts and opinions expressed in this essay are my own and do not reflect those of my employer.

Table of Contents

1. Abstract

2. Introduction: The Great Healthcare Tech IPO Awakening

3. The Cohort: Mapping the Healthcare Tech IPO Landscape

4. Employment Models: The Physician Factor

5. Insurance Operations: Premium Collection and Claims Processing

6. The Pure Tech Vendor Reality

7. Performance Analysis: Who Weathered the Storm?

8. Strategic Implications for Entrepreneurs and Investors

9. Conclusion: The Provider-Payer Advantage Thesis

Abstract

This analysis examines the public market performance of venture-backed healthcare technology companies that went public between 2019-2024, with specific focus on their business models regarding physician employment and insurance operations. Through evaluation of companies like Clover Health, Teladoc, Hims & Hers, GoodRx, Progyny, and others, we find that:

• Companies employing physicians and billing insurance demonstrated greater resilience

• Tech-enabled payers with both member enrollment and claims processing showed stronger fundamentals

• Pure technology vendors faced the most significant market pressure and volatility

• Provider-adjacent models with direct care delivery maintained better unit economics

• The pandemic acceleration created inflated expectations that pure tech plays struggled to sustain

The findings suggest that healthcare technology companies with direct care delivery responsibilities or insurance risk assumption develop more defensible moats and sustainable revenue models than pure software vendors serving healthcare stakeholders.

---

The healthcare technology sector experienced an unprecedented boom in initial public offerings between 2019 and 2024, creating a natural laboratory for understanding which business models demonstrate genuine resilience in public markets. Unlike the biotech and medical device sectors, which operate under fundamentally different regulatory and development paradigms, pure-play healthcare technology companies faced the unique challenge of proving their value propositions could scale profitably while navigating the complex dynamics of American healthcare delivery and payment systems.

The COVID-19 pandemic served as both accelerant and stress test for these companies, dramatically increasing demand for digital health solutions while simultaneously creating unsustainable expectations for growth trajectories. As markets corrected through 2022-2024, the divergent performance patterns among different healthcare technology business models became starkly apparent, offering crucial insights for entrepreneurs and investors evaluating where to deploy capital in this sector.

This analysis focuses specifically on companies that went public as technology-first organizations rather than traditional healthcare providers or payers that subsequently adopted digital capabilities. The distinction matters because venture-backed healthcare technology companies were built from inception around technology-enabled business models, making their public market performance a more accurate reflection of the viability of different approaches to healthcare technology entrepreneurship.

The companies examined represent three distinct categories of healthcare technology business models: those that employ physicians and bill insurance directly, those that operate as tech-enabled payers managing risk and processing claims, and those that function as pure technology vendors selling software or platforms to other healthcare stakeholders. The performance divergence among these models provides compelling evidence about where sustainable value creation occurs in healthcare technology.

The Cohort: Mapping the Healthcare Tech IPO Landscape

The healthcare technology IPO wave of 2019-2024 produced a diverse ecosystem of companies, each representing different approaches to digitizing healthcare delivery and administration. Understanding the business model taxonomy of these companies reveals fundamental differences in how they generate revenue, manage risk, and create defensible competitive positions.

Clover Health emerged as perhaps the most prominent tech-enabled payer, going public via SPAC in 2021 with a valuation exceeding three billion dollars. The company operates as a Medicare Advantage plan, collecting premiums from members and paying claims for their healthcare services while using proprietary technology to manage population health and reduce costs. This dual role as both technology company and insurance entity created unique advantages and challenges that became evident in their public market performance.

Teladoc Health, having gone public earlier but experiencing massive growth during the pandemic period, represents the largest pure-play telehealth provider employing physicians and billing insurance for virtual consultations. The company's acquisition of Livongo for 18.5 billion dollars created a combined entity focused on both episodic care delivery and chronic disease management, positioning it as a comprehensive virtual care platform with direct clinical responsibilities.

One Medical, which Amazon subsequently acquired, operated membership-based primary care clinics combining physical locations with digital capabilities. The company employed physicians, operated medical facilities, and billed insurance for services while charging additional membership fees, representing a hybrid model between traditional primary care and technology-enabled healthcare delivery.

Hims & Hers Health pioneered the direct-to-consumer telehealth model, employing physicians to provide consultations while also operating as a pharmacy benefit manager and direct pharmaceutical distributor. This vertical integration allowed the company to capture revenue across multiple points in the healthcare value chain while maintaining control over the entire patient experience from consultation through medication fulfillment.

GoodRx established itself as a pure technology vendor, providing price transparency tools and discount programs for prescription medications without employing physicians or processing insurance claims. The company generates revenue through referral fees from pharmacy benefit managers and subscription services, representing the classic software-as-a-service model applied to healthcare price discovery.

Progyny focuses specifically on fertility and family planning benefits, operating as a specialized payer that contracts with employers to provide comprehensive reproductive health coverage. The company both enrolls members through employer relationships and processes claims for fertility treatments, combining technology platforms with specialized insurance operations in a high-value healthcare vertical.

Doximity created a professional networking platform specifically for physicians, generating revenue through pharmaceutical company advertising and recruitment services without directly employing healthcare providers or processing patient care transactions. This approach represents the pure technology vendor model applied to healthcare professional services rather than patient care delivery.

The diversity of business models within this cohort provides an ideal natural experiment for understanding which approaches to healthcare technology create sustainable competitive advantages and demonstrate resilience through economic cycles and market corrections.

Employment Models: The Physician Factor